Fundraising Fox
Spirovant
Philadelphia, US · 2 known investors
Find your way into Spirovant
Sign up to see every warm intro you have to Spirovant
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Spirovant team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Spirovant is a gene therapy company developing treatments for cystic fibrosis and other respiratory diseases, including viral vector-based therapies for airway epithelia. It is based in Philadelphia's Life Sciences Corridor.
Founders & leadership
JL
EY
Eric YuenCo-founder & Chief Medical Advisor (former CMO)Eric Yuen holds an M.D. from the University of Chicago and completed neurology residency and fellowships at UCSF; he spent 7 years in academic medicine at the University of Washington researching neurological diseases and over 20 years in pharmaceutical development in clinical and CMO roles across Merck, Johnson & Johnson, Ultragenyx, RiboNova, and Inozyme before co-founding Talee Bio, which was acquired and spun out as Spirovant Sciences in 2024.
JH
Jane HollingsworthCo-founder & Executive Chair of the BoardJane Hollingsworth is co-founder and executive chair of Spirovant, a gene therapy company developing treatments for cystic fibrosis and other respiratory diseases. She founded and manages Militia Hill Ventures, has led the founding and public listing of two biopharmaceutical companies, and held senior management roles at a multinational clinical research organization.
RK
Roland KolbeckChief Scientific Officer & Co-ownerRoland Kolbeck has over 20 years of experience in respiratory, inflammation, and autoimmune research, including contributions to the development of Fasenra® for severe asthma treatment. He is Chief Scientific Officer and co-owner of Spirovant, a Philadelphia-based gene therapy company developing treatments for cystic fibrosis and other respiratory diseases.
EP
Eric PastorChief Technology OfficerEric Pastor is Chief Technology Officer of Spirovant, a gene therapy company developing treatments for cystic fibrosis and other respiratory diseases. He has over 25 years of experience in gene therapy manufacturing and quality (CMC), including leading process development, analytical development, formulation, and regulatory functions across multiple programs through clinical and commercial stages.
DW
David WhitwellChief Financial OfficerDavid Whitwell is Chief Financial Officer of Spirovant, a gene therapy company developing treatments for cystic fibrosis and other respiratory diseases. He brings over 30 years of experience in CFO and strategic advisory services, with expertise in financial planning, fundraising, and business operations.
Investors · 2
Militia Hill Ventureslisted by Militia Hill VenturesPhiladelphia
How we know: Militia Hill Ventures's portfolio page · funding news · Not right? Tell us
BioAdvancereportedConshohocken · $500K – $1.5M
How we know: funding news · Not right? Tell us
In the news
Frequently asked questions
- What does Spirovant do?
- Spirovant is a gene therapy company developing treatments for cystic fibrosis and other respiratory diseases, including viral vector-based therapies for airway epithelia. It is based in Philadelphia's Life Sciences Corridor.
- Who founded Spirovant?
- Spirovant was founded by Joan Lau, Eric Yuen, Jane Hollingsworth.
- Who are Spirovant's investors?
- Spirovant's investors include Militia Hill Ventures, BioAdvance.
- Where is Spirovant headquartered?
- Spirovant is headquartered in Philadelphia, US.